{"doi":"10.1093/ije/dyaf037","title":"Data Resource Profile Update: The Opioid Agonist Treatment and Safety II (OATS II) Study, 2001–22, New South Wales, Australia","abstract":"Data resource basicsAlthough medicines such as methadone and buprenorphine are established as the most effective treatment for opioid dependence, there are risks associated with opioid agonist treatment (OAT), especially at the start [1][2][3].Previous studies have illustrated that the benefits have outweighed the risks.Whilst on treatment, evidence of reductions in the risk of death, opioid use, HIV, and hepatitis C infection has been documented [4][5][6].The use and costs associated with the health service and the criminal justice system are also reduced while people are retained in .There is less evidence of the benefits of OAT in subpopulations, such as pregnant women and older people.This data resource (OATS II) has been constructed for a population-based, retrospective cohort study through a single data linkage .It is an update to the Opioid Agonist Treatment and Safety (OATS) study [12], which was established to determine the incidence of adverse clinical events.Medicines that were available during this updated study period included methadone, buprenorphine, buprenorphine-naloxone, and long-acting injectable buprenorphine (LAIB).The resource includes all people who were approved to receive OAT for opioid dependence in New South Wales (NSW), Australia, through the NSW Opioid Treatment Program between 1 January 2001 and 30 November 2022 (N 55 160).These approvals are recorded in the Controlled Drugs Data Collection (CoDDaC), which is a revised and updated version of the Electronic Reporting and Recording of Controlled Drugs database (used in OATS originally).The CoDDaC includes basic demographic data, drugs of concern, and dates of applications to prescribe OAT.The prescriber, prescribing setting (e.g.primary care, public clinic, private clinic, correctional center, hospital), and dispensing setting (e.g.clinic, community pharmacy, correctional center) are provided.An episode of OAT commences once approval has been granted and continues through multiple dosing occasions and changes in medication, prescriber or dosing location, and concludes once the prescriber has submitted the treatment exit form or is cancelled at the last Key Features The Opioid Agonist Treatment and Safety (OATS II) Study utilizes an updated version of the NSW Opioid Treatment Program data collection to extend the existing OATS Study data collection by 4 years. Additional data collections have been linked: ambulance callouts, infectious disease notifications (including hepatitis C), perinatal health, and cancer notifications.Additional hospital admission cost weight variables are included. The study contains all participants of the NSW Opioid Treatment Program between 2001 and 2022 (N55 160): 69% male and a median age of 31 years at cohort entry. This new data collection enables assessment of health and social outcomes following the introduction of long-acting injectable buprenorphine and estimation of health service utilization costs; expanded outcome variables include all pregnancy and neonatal outcomes, cancer, and infectious disease notifications.","journal":"International Journal of Epidemiology","year":2025,"id":523032,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":38.7,"corpus_rank":7800,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.9029,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1395495,"name":"Fathima Nimnaz Ghouse","orcid":null,"position":1,"is_corresponding":false},{"id":1395496,"name":"Amy Gibson","orcid":null,"position":2,"is_corresponding":false},{"id":1173579,"name":"Duong Thuy Tran","orcid":"0000-0002-1454-9462","position":3,"is_corresponding":false},{"id":301342,"name":"Thomas Santo","orcid":"0000-0002-1218-3946","position":4,"is_corresponding":false},{"id":615578,"name":"Chrianna Bharat","orcid":"0000-0002-9778-0386","position":5,"is_corresponding":false},{"id":236614,"name":"Michael Farrell","orcid":"0000-0001-7008-8130","position":6,"is_corresponding":false},{"id":22455,"name":"Louisa Degenhardt","orcid":"0000-0002-8513-2218","position":7,"is_corresponding":false},{"id":332528,"name":"N. R. Jones","orcid":"0000-0002-5742-4598","position":0,"is_corresponding":true}],"reference_count":29,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:49:58.707747Z","pmid":"40187894","pmcid":"PMC11972115","fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}